For more than forty years, ivermectin has stood as humanity's primary shield against parasitic nematodes in both livestock and human populations, but the relentless pressure of its own success has quietly cultivated resistance. Now, researchers have identified a specific molecular gatekeeper — a protein called PGP-9 — that actively expels the drug from parasite cells before it can do its work, explaining a resistance mechanism that has been spreading across species and continents. The discovery, made through precise gene editing in laboratory nematodes and confirmed using proteins drawn from r
PGP-9 protein identified as key driver of ivermectin resistance in parasitic nematodes
PGP-9 acts as a gatekeeper, limiting ivermectin bioavailability
Mark
So this paper identifies PGP-9 as the key driver of ivermectin resistance. But the researchers tested six different pgp genes. Why did only pgp-9 matter so much?
Mimi
That's the interesting part. In the resistant background they were studying, only pgp-9 and pgp-3 showed significant effects when deleted. The other four had essentially no impact. It suggests that when parasites evolve resistance through repeated drug exposure, they don't activate all available defense mechanisms equally—they rely on a narrower set of dominant pumps.
Luke
But here's a caution: they only tested individual deletions. They didn't look at what happens when you delete pgp-9 together with pgp-3, or pgp-9 with pgp-6. There could be compensatory mechanisms they didn't see. And they acknowledge this limitation themselves.
Mimi
True. But the rescue experiments are pretty convincing. When they put pgp-9 back into the knockout strain, resistance came back. And they tested it in two other independently derived resistant strains using RNA interference, and got consistent results.
Mark
What about the fluorescent ivermectin they developed? How confident should we be that it behaves like the real drug?
Luke
This is worth flagging. F-IVM is structurally modified—it lost two hydroxyl groups to gain fluorescence. That change reduced its potency about a thousandfold. The researchers argue the physicochemical properties are similar enough that transport dynamics should be conserved, but that's an inference, not a direct proof.
Mimi
They did test F-IVM's behavior in both susceptible and resistant worms and saw the expected cross-resistance pattern. And the accumulation patterns they observed—high in susceptible worms, low in resistant ones, restored in pgp-9 knockouts—all align with the genetic data. That's a pretty strong consistency check.
Mark
And the conservation across species? They showed the H. contortus version of PGP-9 could rescue the C. elegans knockout.
Mimi
Yes, and that's significant because it suggests the mechanism isn't just a laboratory artifact. If the same protein works the same way in a parasitic nematode, it's more likely to matter in real infections.
Luke
But C. elegans is still a model organism. The researchers themselves note that extrapolating from C. elegans to parasitic nematodes requires caution. They mention that tissue-specific expression patterns could differ between species, and they haven't done comparative localization studies in H. contortus yet. So we know the protein is functionally conserved, but we don't know if it's expressed in the same tissues or at the same levels in the actual parasite.
Mark
What's the practical implication here? Does this finding suggest a way to combat resistance?
Mimi
The authors propose that understanding PGP-9's role could help develop strategies to slow resistance spread—potentially through transporter inhibitors or combination therapies. If you could block PGP-9, you might restore ivermectin sensitivity in resistant populations.
Luke
That's speculative at this point. They haven't tested any inhibitors. And there's a question of whether blocking PGP-9 would have off-target effects—the protein likely has other physiological roles beyond drug resistance. The neuronal expression they found, for instance, suggests it might be involved in detoxification of other xenobiotics too.
The Pulse
- Ivermectin resistance is no longer a theoretical concern — it is actively undermining parasite control in livestock and threatening programs that protect millions of people from river blindness.
- The pharmaceutical pipeline for new antiparasitic drugs has largely run dry, making the spread of resistance an urgent crisis with few obvious exits.
- Using CRISPR-Cas9 gene editing, researchers deleted six candidate pump-proteins in resistant worms and found that removing PGP-9 alone was enough to fully erase the resistance phenotype in motility assays — a result described as striking even by cautious scientific standards.
- A fluorescent ivermectin tracer revealed the mechanism in real time: resistant worms actively expel the drug at intestinal barriers, while worms lacking PGP-9 accumulate drug at levels indistinguishable from fully susceptible animals.
- The resistance mechanism was confirmed to cross species lines — a PGP-9 protein borrowed from the livestock parasite Haemonchus contortus restored resistance in edited laboratory worms, signaling that the findings are not confined to the lab.
- The path forward may lie in combination therapies or PGP-9 inhibitors that block the pump before it can act, potentially reviving ivermectin's effectiveness in populations where it has already begun to fail.
For more than forty years, ivermectin has stood as humanity's primary shield against parasitic nematodes in both livestock and human populations, but the relentless pressure of its own success has quietly cultivated resistance. Now, researchers have identified a specific molecular gatekeeper — a protein called PGP-9 — that actively expels the drug from parasite cells before it can do its work, explaining a resistance mechanism that has been spreading across species and continents. The discovery, made through precise gene editing in laboratory nematodes and confirmed using proteins drawn from real livestock parasites, offers science its clearest view yet of how these organisms survive treatment. In naming the mechanism, researchers have also named a target — and with it, the possibility of restoring a medicine the world cannot yet afford to lose.
Ivermectin has anchored parasite control for more than four decades, deployed widely against gastrointestinal worms in livestock and filarial infections in humans. But intensive use created the conditions for its own undoing. Resistance has emerged and is spreading — economically devastating in small ruminants, and increasingly worrying in the filarial worm responsible for river blindness. With few new antiparasitic drugs in development, understanding how resistance works has become a matter of genuine urgency.
Researchers had long suspected that P-glycoproteins — membrane-embedded molecular pumps that expel drugs from cells — were central to the problem. Gene expression studies showed these pumps were elevated in resistant parasites, and blocking them in the lab could restore drug sensitivity. But which specific pump mattered most had never been directly tested in a living resistant organism.
To find out, a research team used CRISPR-Cas9 to delete six different pgp genes, one at a time, in a strain of Caenorhabditis elegans that had been bred for ivermectin resistance. The answer was unambiguous: deleting pgp-9 produced the strongest effect by far. In larval development assays, the deletion tripled drug sensitivity. In motility assays measuring paralysis, it erased the resistance phenotype entirely. When the gene was restored, resistance returned — confirming causation rather than coincidence.
The team then asked whether the mechanism extended beyond their laboratory strain. Silencing pgp-9 in two independently derived resistant lines consistently reduced resistance. More compellingly, when they expressed the pgp-9 gene from Haemonchus contortus — a nematode that causes serious disease in livestock — in their edited worms, the parasitic protein restored resistance to original levels. The mechanism is conserved across species.
To visualize how PGP-9 works, the researchers developed a fluorescent form of ivermectin and tracked its movement through living worms. In susceptible animals, the drug accumulated heavily in the pharynx and intestine. In resistant worms, fluorescence was minimal — the drug was being actively expelled. Deleting pgp-9 restored accumulation to susceptible levels, and the researchers confirmed that resistant worms were not simply ingesting less drug; their pharyngeal pumping rates were identical to susceptible ones.
Mapping where PGP-9 is expressed completed the picture: the protein sits in the pharyngeal bulbs, intestine, and head neurons — precisely the physiological barriers where ivermectin enters the organism. PGP-9 functions as a gatekeeper, intercepting the drug before it can reach the concentrations needed to paralyze and kill. The findings point toward potential strategies — inhibitors that neutralize the pump, or combination therapies — that could restore ivermectin's effectiveness in populations where resistance has already taken hold.
Ivermectin has been the workhorse of parasite control for more than four decades. Since its market release in 1981, the drug has been administered to livestock and humans on a massive scale, saving animals from gastrointestinal parasites and protecting people from filarial infections. But success bred its own problem. Intensive use created the conditions for resistance to emerge, and now that resistance is spreading. In livestock, particularly in small ruminants, the economic toll is severe. In humans, resistance in the filarial worm Onchocerca volvulus—treated with ivermectin for river blindness—is becoming a growing concern. The pharmaceutical pipeline for new antihelmintics has largely dried up, which means understanding how parasites develop resistance has become urgent.
Researchers have long suspected that a family of proteins called P-glycoproteins, or PGPs, play a central role in this resistance. These are molecular pumps embedded in cell membranes that actively expel drugs from cells—a kind of cellular defense mechanism. Previous studies showed that genes encoding these pumps were upregulated in resistant parasites, and that blocking them in the lab could restore drug sensitivity. But which specific PGP mattered most remained unclear. The parasite world contains a broad repertoire of pgp genes, and their individual contributions to resistance had never been directly tested in a living, resistant organism.
A team of researchers turned to a model nematode, Caenorhabditis elegans, and specifically to a strain called IVR10 that had been selected for ivermectin resistance through repeated exposure to the drug. Using CRISPR-Cas9 gene editing, they systematically deleted six different pgp genes—pgp-1, pgp-3, pgp-6, pgp-9, pgp-11, and pgp-13—in the resistant background. Then they tested how each deletion affected the worms' sensitivity to ivermectin. The results were striking: only two deletions made a meaningful difference. Removing pgp-9 produced the strongest effect. In a larval development assay, deleting pgp-9 reduced the concentration of drug needed to kill half the population from 11.22 nanomolar to 3.98 nanomolar—a threefold increase in sensitivity. In a motility assay measuring paralysis, the effect was even more dramatic: pgp-9 deletion completely restored normal drug sensitivity, erasing the resistance phenotype entirely.
To confirm that pgp-9 deletion was actually responsible for this hypersensitivity, the researchers restored the gene in the knockout strain. When pgp-9 was put back under its native promoter, resistance returned. The team then tested whether this finding held in other independently derived resistant strains. In two additional resistant lines, silencing pgp-9 through RNA interference consistently reduced resistance, though the effect was more modest than in the knockout. They also showed that deleting pgp-9 in a normal, drug-susceptible strain made it even more sensitive to ivermectin, confirming that PGP-9 plays a protective role across genetic backgrounds.
The next question was whether this mechanism was conserved in actual parasites. The researchers expressed the pgp-9 gene from Haemonchus contortus, a gastrointestinal nematode that causes serious disease in livestock, in the C. elegans knockout strain. The parasitic version of the protein worked. It restored resistance to levels comparable to the original resistant worm. This demonstrated that PGP-9 function is conserved across nematode species—a finding with real implications for understanding resistance in the field.
To visualize exactly how PGP-9 confers resistance, the team developed a fluorescent derivative of ivermectin, F-IVM. This allowed them to track where the drug accumulates in living worms. In susceptible worms, F-IVM accumulated heavily in the pharynx and intestine—the major sites of drug uptake. In resistant worms, fluorescence was minimal, suggesting the drug was being actively pumped out. Critically, when pgp-9 was deleted, drug accumulation returned to levels seen in susceptible worms, particularly at the intestinal barrier. Quantitative analysis confirmed that resistant worms had twofold less drug accumulation than susceptible ones, and that this difference disappeared when pgp-9 was removed. The researchers also confirmed that the resistant worms were not simply taking up less drug—their pharyngeal pumping rates were identical to susceptible worms, ruling out reduced ingestion as an explanation.
Final experiments mapped where pgp-9 is expressed. The protein appeared in the pharyngeal bulbs, throughout the intestine, and in head neurons—all strategic physiological barriers where a drug-pumping transporter could limit drug entry and accumulation. This tissue-specific localization helps explain why PGP-9 is so effective at conferring resistance: it sits at the gates where ivermectin enters the organism. The findings suggest a model in which PGP-9 acts as a gatekeeper, actively preventing drug from reaching the concentrations needed to paralyze and kill the worm. Understanding this mechanism may open paths toward new strategies—perhaps inhibitors that block PGP-9 function, or combination therapies that could restore the effectiveness of ivermectin in resistant populations.
Notable Quotes
PGP-9 is located on strategic physiological barriers, and therefore influences IVM accumulation and susceptibility— Study authors, discussing PGP-9 tissue localization
Understanding the multifaceted processes underlying resistance remains an urgent challenge— Study authors, in author summary
Want the full story?
Read the original at PLOS (Public Library of Science) ↗
Health & Medicine